NICE
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
The centralised procedure was created in 1995 to facilitate access to innovative medicines across the European Union. Since then the scope of authorisation via the centralised…
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice”…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The…
New OHE Research Paper: Uncertainty and Risk in HTA Decision Making
7 December 2016
A new OHE Research Paper has just been published on the topic of uncertainty and risk in health technology assessment (HTA) decision making. The report is…
Presentations and Posters from ISPOR Europe 2016
24 November 2016
ISPOR’s 19th Annual European Congress was held in Vienna, 29 October – 2 November 2016. Several members of the OHE team attended and contributed to the…
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
ISPOR’s 19th Annual European Congress is scheduled for 29 October – 2 November 2016 in Vienna. This post contains a summary of the contributions by various…
OHE at Priorities 2016: Valuing Health at the End of Life and MCDA for Priority Setting
19 September 2016
OHE’s Koonal Shah presented findings from his review of public preferences regarding end of life treatments at the Priorities 2016 conference in Birmingham. Martina Garau chaired…
OHE and ABPI Webinar: New EQ-5D-5L value sets for England and the UK and Implications for HTA
11 July 2016
The Association of the British Pharmaceutical Industry, in conjunction with the Office of Health Economics, invites you to register for a webinar on Monday 18th July:…
New Publication: Opportunity Costs and Local Health Service Spending Decisions – A Qualitative Study from Wales
26 April 2016
Work by Sarah Karlsberg Schaffer (OHE), Jon Sussex (RAND Europe), Dyfrig Hughes (Bangor University) and Nancy Devlin (OHE) has recently been published in BMC Health Services…